Τίτλος:
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
For patients with newly diagnosed multiple myeloma (NDMM) who are transplant ineligible, bortezomib-melphalan-prednisone (VMP) demonstrated superior efficacy based on the VISTA trial. In subsequent trials, twice-weekly bortezomib was limited to the first cycle or completely replaced with once-weekly bortezomib to reduce toxicity. Following a systematic literature review, the efficacy and safety of modified VMP schedules (pooled data from the once-weekly bortezomib VMP arm of the GIMEMA trial and the VMP arm of the ALCYONE trial) were compared to the VISTA schedule using naïve and unanchored matching-adjusted indirect comparison (MAIC). Median progression-free survival was similar between VISTA and modified VMP (20.7 months [95% CI, 18.4–24.3] vs 19.6 months [95% CI, 18.8–21.0]). Peripheral neuropathy was significantly reduced with modified VMP versus VISTA VMP (all grades: naïve, 32.1% vs 46.8% and MAIC, 32.1% vs 46.7%; both p <.0001). These findings support a modified VMP dosing schedule for patients with NDMM who are transplant ineligible. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
Συγγραφείς:
Mateos, M.-V.
San-Miguel, J.
Goldschmidt, H.
Sonneveld, P.
Dimopoulos, M.A.
Heeg, B.
Hashim, M.
Deraedt, W.
Hu, P.
Lam, A.
He, J.
Περιοδικό:
Clinical Lymphoma Myeloma and Leukemia
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
bortezomib; daratumumab; melphalan; prednisone; thalidomide; antineoplastic agent; bortezomib; melphalan; prednisone, anemia; Article; cancer combination chemotherapy; cancer survival; drug efficacy; drug safety; drug withdrawal; human; infection; infusion related reaction; multiple cycle treatment; multiple myeloma; neutropenia; peripheral neuropathy; priority journal; progression free survival; systematic review; thrombocytopenia; multiple myeloma; treatment outcome, Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Treatment Outcome
DOI:
10.1080/10428194.2019.1675881
